Illumina, Inc. Post Earnings: Buy On A Pullback

Impact · against what's priced in

Illumina's Q2 beat and raised full-year guidance provide a tangible catalyst for price appreciation. The shift in analyst sentiment toward a 2027 revenue breakout suggests the market is beginning to price in a growth inflection after a period of stagnation.

ILMN+0.70

No priced-in read yet

In context

The company beat Q2 expectations and raised full-year revenue and EPS guidance, while analysts are now pricing in a potential revenue breakout by 2027.

Read from the article alone

• earnings▲5%
• revenue
• guidance
• cash flow
• biotech
• ILMN
• genomics
• profitability
• share buybacks